scholarly journals PD-1 inhibitors versus PD-L1 inhibitors in addition to chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

2021 ◽  
pp. 100214
Author(s):  
Alessandro Di Federico ◽  
Andrea De Giglio ◽  
Claudia Parisi ◽  
Francesco Gelsomino ◽  
Luca Boni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis

2018 ◽  
Vol 10 (12) ◽  
pp. 6677-6694 ◽  
Author(s):  
Lisa M. Hess ◽  
Amy M. DeLozier ◽  
Fanni Natanegara ◽  
Xiaofei Wang ◽  
Victoria Soldatenkova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

scholarly journals Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis

Immunotherapy ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 407-428 ◽  
Author(s):  
Andrew M Frederickson ◽  
Stella Arndorfer ◽  
Ina Zhang ◽  
Maria Lorenzi ◽  
Ralph Insinga ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment

Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer – a meta-analysis

Immunotherapy ◽  
2021 ◽  
Author(s):  
Ching-Yi Chen ◽  
Wang-Chun Chen ◽  
Chao-Ming Hung ◽  
Yu-Feng Wei
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Extensive Stage ◽  
First Line Treatment

This meta-analysis investigated the clinical benefits of chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). Seven randomized controlled trials with a total of 2862 patients were analyzed. Compared with chemotherapy alone, chemo-immunotherapy provided a better progression-free survival (PFS) with a hazard ratio (HR) of 0.81, p < 0.00001, and overall survival (OS) with a HR of 0.82, p < 0.0001; however, the incidence of treatment-related adverse effects (TRAEs) was significantly increased. Subgroup analyses showed that good performance status, cisplatin-based chemotherapy, without brain metastases at baseline and non-Asian populations were associated with greater benefits in OS from chemo-immunotherapy. Chemo-immunotherapy demonstrated better PFS and OS compared with chemotherapy alone as first line treatment in ES-SCLC, but additional TRAEs should be closely monitored.

Sign in / Sign up

Export Citation Format

Share Document